Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development

Ambati, Jayakrishna; Magagnoli, Joseph; Leung, Hannah; Wang, Shao-Bin; Andrews, Chris; Fu, Dongxu; Pandey, Akshat; Sahu, Srabani; Narendran, Siddharth; Hirahara, Shuichiro; Fukuda, Shin‐ichi; Sun, Jian; Pandya, Lekha; Ambati, Meenakshi; Pereira, Felipe; Varshney, Akhil; H. Cummings, Tammy; W. Hardin, James; Edun, Babatunde; L. Bennett, Charles; Ambati, Kameshwari; J. Fowler, Benjamin; Kerur, Nagaraj; Röver, Christian; Leitinger, Norbert; C. Werner, Brian; D. Stein, Joshua; Scott Sutton, S.; D. Gelfand, Bradley

doi:10.1038/s41467-020-18528-z

Public

Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development

Published in Nature Communications • Sep 23, 2020

Authors:

Jayakrishna Ambati

Joseph Magagnoli

Hannah Leung

Abstract

Innate immune signaling through the NLRP3 inflammasome is activated by multiple diabetes-related stressors, but whether targeting the inflammasome is beneficial for diabetes is still unclear. Nucleoside reverse-transcriptase inhibitors (NRTI), drugs approved to treat HIV-1 and hepatitis B infections...

Subject

Inflammasome

Type 2 diabetes

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!